Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $3.38 USD
Change Today +0.07 / 2.11%
Volume 696.5K
ONTY On Other Exchanges
As of 8:10 PM 11/25/15 All times are local (Market data is delayed by at least 15 minutes).

oncothyreon inc (ONTY) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/1/15 - $4.69
52 Week Low
05/5/15 - $1.41
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ONCOTHYREON INC (ONTY)

oncothyreon inc (ONTY) Related Businessweek News

No Related Businessweek News Found

oncothyreon inc (ONTY) Details

Oncothyreon Inc., a clinical-stage biopharmaceutical company, engages in the research and development of therapeutic products for the treatment of cancer. Its clinical-stage product candidates include ONT-380, an orally active and selective small-molecule HER2 inhibitor, which is in two Phase 1b trials, one in combination with Kadcyla and another in combination with Xeloda and/or Herceptin; and ONT-10, a therapeutic vaccine in Phase 1 trial targeting the Mucin 1 peptide antigen (MUC1) for use in various cancer indications, including breast, thyroid, colon, stomach, pancreas, ovarian, and prostate, as well as certain types of lung cancer. The company is also developing Checkpoint kinase 1, a protein kinase in pre-clinical studies to inhibit tumor growth as single agents. In addition, it focuses on researching on Protocells, which are nanoparticles designed to enable the targeted delivery of various therapeutic agents, including nucleic acids, proteins, peptides, and small molecules, as well as to develop product candidates for the treatment of cancer and rare diseases. The company has a research collaboration agreement with Sentinel Oncology Ltd. for the discovery of novel Chk1 inhibitors; collaboration with Celldex Therapeutics, Inc. on a combined clinical trial of ONT-10 and varlilumab; and collaboration with Adimab LLC for the discovery of novel antibodies against undisclosed immunotherapy targets in oncology. Oncothyreon Inc. was founded in 1985 and is headquartered in Seattle, Washington.

49 Employees
Last Reported Date: 03/10/15
Founded in 1985

oncothyreon inc (ONTY) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $435.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $276.0K
Chief Operating Officer
Total Annual Compensation: $310.0K
Chief Medical Officer
Total Annual Compensation: $355.0K
Chief Scientific Officer
Total Annual Compensation: $270.5K
Compensation as of Fiscal Year 2014.

oncothyreon inc (ONTY) Key Developments

Oncothyreon Inc. Reports Consolidated Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2015; Provides cash flow Guidance for 2015

ONCOTHYREON INC. reported consolidated unaudited earnings results for the third quarter and nine months ended September 30, 2015. For the quarter, the company reported loss from operations of $7,222,000 compared with $8,020,000 for the same period last year. Net loss was $4,619,000 or $0.05 basic and diluted compared with $6,736,000 $0.09 basic and diluted for the same period last year. The decrease in net loss was also due to decreases in research and development expenses of $0.5 million and decreases in general and administrative expenses of $0.3 million. For the nine months, loss from operations of $23,638,000 compared with $22,977,000 for the same period last year. Net loss was $23,450,000 $0.24 basic and diluted compared with $22,384,000 $0.31 basic and diluted for the same period last year. The company currently expects operating expenses in 2015 to be lower than in 2014, which included the upfront payment to Array BioPharma Inc. for the exclusive license to ONT-380. The company currently expects cash used in operations in 2015 to be approximately $30.0 million - $32.0 million.

Oncothyreon Inc, Q3 2015 Earnings Call, Nov 05, 2015

Oncothyreon Inc, Q3 2015 Earnings Call, Nov 05, 2015

Oncothyreon Inc Presents at BIO-Europe 2015, Nov-02-2015

Oncothyreon Inc Presents at BIO-Europe 2015, Nov-02-2015 . Venue: Munich, Germany.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ONTY:US $3.38 USD +0.07

ONTY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ONTY.
View Industry Companies

Industry Analysis


Industry Average

Valuation ONTY Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 3.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact ONCOTHYREON INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at